Disclaimer: This is an international website for VOTRIENT® (pazopanib) and is intended for health care professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
Eligibility criteria: patients aged ≥18 years with advanced and/or metastatic RCC with progression on 1 prior cytokine-based systemic therapy, clear cell histology, measurable disease, ECOG performance status ≤1, and adequate organ function.
Eligibility criteria: patients aged ≥18 years with advanced RCC, clear cell histology, no prior systemic therapy, measurable disease KPS ≥70%, and adequate organ function.